Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 16/20 | 0.82 |
| ▸ | MMP2 | P08253 | 6/20 | 0.82 |
| ▸ | MMP13 | P45452 | 12/20 | 0.50 |
| ▸ | MMP8 | P22894 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MMP1 | P03956 | 9/20 | 0.48 |
| ▸ | ADAM17 | P78536 | 6/20 | 0.48 |
| ▸ | MMP3 | P08254 | 1/20 | 0.48 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.47 |
| ▸ | BMP1 | P13497 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13639188 | 1.00 | MMP9 (0.82) | MMP9MMP2MMP13MMP8ALDH1A1 | |
| SCHEMBL13639215 | 0.90 | MMP9 (1.00) | MMP9MMP2MMP13MMP8ALDH1A1 | |
| SCHEMBL13639235 | 0.90 | MMP9 (1.00) | MMP9MMP2MMP13MMP8ALDH1A1 | |
| SCHEMBL13639191 | 0.90 | MMP9 (0.66) | MMP9MMP2MMP13MMP8ALDH1A1 | |
| SCHEMBL13639263 | 0.90 | MMP9 (0.66) | MMP9MMP2MMP13MMP8ALDH1A1 | |
| SCHEMBL13639255 | 0.90 | MMP9 (0.65) | MMP9MMP2MMP13MMP8ALDH1A1 | |
| SCHEMBL13639199 | 0.90 | MMP9 (0.65) | MMP9MMP2MMP13MMP8ALDH1A1 | |
| SCHEMBL13639280 | 0.88 | MMP9 (0.64) | MMP9MMP2MMP13MMP8ALDH1A1 | |
| SCHEMBL13639258 | 0.88 | MMP9 (0.64) | MMP9MMP2MMP13MMP8ALDH1A1 | |
| SCHEMBL13639262 | 0.88 | MMP9 (0.80) | MMP9MMP2MMP13MMP8ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120282180-A1 | Compounds with Matrix-Metalloproteinase Inhibitory Activity and Imaging Agents Thereof | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2012-11-08 | — | — | US | disclosed |
| US-20120282180-A1 | Compounds with Matrix-Metalloproteinase Inhibitory Activity and Imaging Agents Thereof | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2012-11-08 | — | — | US | disclosed |
| EP-2520573-A1 | Compounds with matrix-metalloproteinase inhibitory activity | Westfälische Wilhelms-Universität Münster (DE) | 2012-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120282180-A1 | Compounds with Matrix-Metalloproteinase Inhibitory Activity and Imaging Agents Thereof | MMP1, MMP17, MMP25 | MMP9 4/4885MMP2 16/4885MMP13 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.